Long-acting nifedipine in the management of essential hypertension: a review for cardiologists.

IF 1.3 American journal of cardiovascular disease Pub Date : 2024-12-15 eCollection Date: 2024-01-01 DOI:10.62347/RPMZ6407
Prakash Kumar Hazra, Ashwani Mehta, Bhupen Desai, Umeshwar Pandey, Kapil Dev Mehta, Sarita Bajpai, Deepak Prasad
{"title":"Long-acting nifedipine in the management of essential hypertension: a review for cardiologists.","authors":"Prakash Kumar Hazra, Ashwani Mehta, Bhupen Desai, Umeshwar Pandey, Kapil Dev Mehta, Sarita Bajpai, Deepak Prasad","doi":"10.62347/RPMZ6407","DOIUrl":null,"url":null,"abstract":"<p><p>Calcium channel antagonists, specifically long-acting nifedipine formulations, play a crucial role in treating hypertension and angina. Originally used for angina, nifedipine has been widely employed as an antihypertensive medication for over 40 years. It offers rapid action and oral bioavailability with minimal maternal or fetal side effects, making it suitable for treating hypertensive crises during pregnancy. However, it can cause a sudden drop in blood pressure and tachycardia. Long-acting formulations, such as gastrointestinal therapeutic systems, gradually release nifedipine over 24 hours, mitigating these issues. This review aims to assess the clinical efficacy and safety of long-acting nifedipine formulations in managing essential hypertension, with a focus on improving blood pressure control and addressing challenges in uncontrolled and resistant hypertension. Furthermore, long-acting nifedipine provides therapeutic advantages beyond hypertension management, showing efficacy in treating comorbid conditions such as chronic kidney disease and diabetes. Global studies support its efficacy, suggesting that a shift toward the use of long-acting nifedipine can help address the global hypertension problem and enhance the quality of life for hypertensive patients.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 6","pages":"396-413"},"PeriodicalIF":1.3000,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744219/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cardiovascular disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62347/RPMZ6407","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Calcium channel antagonists, specifically long-acting nifedipine formulations, play a crucial role in treating hypertension and angina. Originally used for angina, nifedipine has been widely employed as an antihypertensive medication for over 40 years. It offers rapid action and oral bioavailability with minimal maternal or fetal side effects, making it suitable for treating hypertensive crises during pregnancy. However, it can cause a sudden drop in blood pressure and tachycardia. Long-acting formulations, such as gastrointestinal therapeutic systems, gradually release nifedipine over 24 hours, mitigating these issues. This review aims to assess the clinical efficacy and safety of long-acting nifedipine formulations in managing essential hypertension, with a focus on improving blood pressure control and addressing challenges in uncontrolled and resistant hypertension. Furthermore, long-acting nifedipine provides therapeutic advantages beyond hypertension management, showing efficacy in treating comorbid conditions such as chronic kidney disease and diabetes. Global studies support its efficacy, suggesting that a shift toward the use of long-acting nifedipine can help address the global hypertension problem and enhance the quality of life for hypertensive patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
长效硝苯地平治疗原发性高血压:心脏病专家综述。
钙通道拮抗剂,特别是长效硝苯地平制剂,在治疗高血压和心绞痛中起着至关重要的作用。硝苯地平最初用于治疗心绞痛,40多年来一直被广泛用作抗高血压药物。它具有快速作用和口服生物利用度,对母体或胎儿的副作用最小,使其适用于治疗妊娠期高血压危象。然而,它会导致血压突然下降和心动过速。长效制剂,如胃肠道治疗系统,在24小时内逐渐释放硝苯地平,减轻这些问题。本综述旨在评估长效硝苯地平制剂治疗原发性高血压的临床疗效和安全性,重点关注改善血压控制和解决未控制和顽固性高血压的挑战。此外,长效硝苯地平在高血压治疗之外还具有治疗优势,对慢性肾病和糖尿病等合并症也有疗效。全球研究支持其疗效,表明转向使用长效硝苯地平有助于解决全球高血压问题,提高高血压患者的生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
American journal of cardiovascular disease
American journal of cardiovascular disease CARDIAC & CARDIOVASCULAR SYSTEMS-
自引率
0.00%
发文量
21
期刊最新文献
Burden and predictors of mortality related to cardiogenic shock in the South Bronx Population. Comparison of long-term outcomes in patients with cardiac sarcoidosis treated with different immunosuppressive drugs. Long-acting nifedipine in the management of essential hypertension: a review for cardiologists. Physical cardiac rehabilitation effects on cardio-metabolic outcomes in the patients with hypertrophic cardiomyopathy: a systematic review. Prevalence of transthyretin cardiac amyloidosis in patients with aortic stenosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1